Medical Oncologist; clinical and translational researcher pancreatic and hepatobiliary cancers. Views are my own 🇮🇪🇨🇦
Joined August 2013
- Tweets948
- Following634
- Followers2K
- Likes14.1K
Grainne O'Kane retweeted
🚨 FDA NEWS |
AZUR 1 Update in #RectalCancer
FDA grants accelerated approval to dostarlimab (Jemperli) for previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer.First immunotherapy in this setting — may allow some patients to avoid chemo, radiation, and surgery.AZUR-1: 68% cCR12, 76% no evidence of disease ≥1 year, no recurrences in responders (median FU >2 yrs). Nearly ¾ of patients avoided surgery/RT/chemo
@CathyEngMD @BenWestphalen @graokane @NiuSanford @AndresC27622123 @GillSharlene @pashtoonkasi @DrVilmaPBarcia @Erman_Akkus @GIMedOnc @UOzkerim @MarioBalsaMD @p_ciracimd @DraMartinezLago @DaisukeKotani @Aiims1742 @ARosen380 @realbowtiedoc @KoheiShitara @GaiaGriguolo @scocmem
Grainne O'Kane retweeted
“It’s been a journey” Shroff told @NBCNews. “I’ve spent my entire life trying to eradicate cancer, primarily pancreatic cancer, but also liver cancers.”
nbcnews.com/health/disease/r…
An homage to Rachna Shroff, including thoughts from her family. Please read, share & honor her memory.
Grainne O'Kane retweeted
This week’s OncoAlert 🚨 Newsletter is OUT! Packed with the latest updates in oncology. subscribe here 👉 buff.ly/N5gYtAc
This week:
• MATTERHORN OS: periop durva + FLOT is the new SOC in gastric/GEJ
• FDA: tucatinib + HP maintenance in HER2+ MBC ( @ErikaHamilton9 )
• S1914: no benefit for atezo + SBRT in early NSCLC
• KEYNOTE-427, STAMINA, VIOLETTE & more
Free, weekly, by colleagues for colleagues 👇
@Uromigos, @matteolambe, @aftimosp, @EdeAzambuja, @DrSGraff, , @doublewhammied, @maryamlustberg, @raalbany, @hoperugo, @stolaney1, @LoiSher, @JaniceTNBCmets, @montypal, @DrDanielHeng, @apoloandrea, @DrChoueiri, @PGrivasMDPhD, @TiansterZhang, @neerajaiims, @amerseburger, @sonpavde, @drenriquegrande, @tompowles1, @cdanicas, @nataliagandur, @realbowtiedoc, @OncoCifu88, @scocmem, @FernandoOnco, @ElisaAgostinett, @tobeelizabeth, @ErmanAkkus, @MarioBalsaMD, @DrMirallas, @GIMedOnc, @UOzkerim, @DrRishabhOnco, @PaulJiL, @DaisukeKotani, @DraMartinezLago, @pciracimd, @BenWestphalen, @CentralParkWMD, @graokane, @AmandaNizamMD
Grainne O'Kane retweeted
The OncoAlert #ESMO26 PULSE Faculty is ready 🇪🇸
@cdanicas, @hoperugo, @DrChoueiri, @TiansterZhang, @matteolambe, @NiuSanford, @stolaney1, @christine_lovly, @amerseburger, @GlopesMd, @tompowles1, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @Icro_Meattini, @BenWestphalen, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus @WeOncologists
Our faculty will report live from Madrid to keep you up to date on the science, whether you're there or at home. OncoAlert Has you Covered!!
Less noise. No nonsense. Just science.
Strictly By Colleagues... For Colleagues!
Grainne O'Kane retweeted
FDA News: REFOCUS Update in #Cholangiocarcinoma
On September 23, 2026, the FDA🇺🇸 approved lirafugratinib for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring FGFR2🧬 fusions or rearrangements.
➡️ In the REFOCUS trial of 116 patients, lirafugratinib achieved a 46% objective response rate and a median duration of response of 11.8 months.
fda.gov/drugs/resources-info…
@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @AndresC27622123, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara, @GaiaGriguolo, @scocmem
Grainne O'Kane retweeted
🔥great news🔥
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma
fda.gov/drugs/resources-info…
👉expanding options for patients with FGFR2 fusions!
@myESMO @ASCO @ILCAnews @EASLedu
Grainne O'Kane retweeted
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or m...
fda.gov/drugs/resources-info…
clin.larvol.com/trial-detail…
#LARVOL #CancerResearch #OncologyInsights #Cholangiocarcinoma #FGFR2 #TargetedTherapy @ArndtVogel @VivekSubbiah @DraMartinezLago @graokane
Grainne O'Kane retweeted
Pancreas cancer a challenge. @CCRTIreland delighted that @EileenMOReilly will discuss exciting new treatments like DARAXONRASIB at our “Dare2Cure” meeting Herbert Park Hotel Ballsbridge Sept 23 630 pm. Patients carers pubic welcome. CCRT.ie
Grainne O'Kane retweeted
Glad to discuss the key findings from the HIMALAYA and SIERRA trials in #HCC, including the long-term survival benefit observed with the #STRIDE regimen. @GiOncNow @HUNIMED @HumanitasMilano
⭐ We recently spoke with @LorenzaRimassa of @HUNIMED on some of the key findings from the HIMALAYA and SIERRA trials in #hepatocellular carcinoma, including the long-term survival benefit observed with the STRIDE regimen: buff.ly/9iN7JDw
Grainne O'Kane retweeted
Another @ILCAnews in the books - celebrating 20 years of science and discovery in Brussels! Love this crew.
A big congratulations to @docamitgs as the new President elect!
And to our amazing Chief resident @RahulSandella for delivering a flawless oral presentation.
Grainne O'Kane retweeted
Day 3 of #ILCA26 is underway, but Day 2 set an incredible bar!
➡️ Tumor Board: Case debates & clinical decision-making
➡️ Ideas to Impact: Strategic vision for ILCA products & global partnerships
➡️ Advocacy: HCC risk policy
Stay tuned for today’s closing address!
Grainne O'Kane retweeted
@ENS_CCA representation at @ILCAnews #ILCA26 meeting with a session on #targetedtherapies and #perioperative treatment for #BiliaryCancer
Great co-chairing @graokane 😊
PD: join our network on enscca.com
Grainne O'Kane retweeted
🧬 Could targeting tumour metabolism with L-glutamine change the treatment landscape for advanced pancreatic cancer?
buff.ly/lBleNyq
L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial
A phase 1 trial explored 🇺🇸 FDA-approved L-glutamine alongside gemcitabine💊 and nab-paclitaxel in 16 patients with treatment-naive, advanced #PancreaticCancer .
➡️ The combination reached its recommended phase 2 dose, with tumor shrinkage in 94% of participants and a 44% overall response rate, including 12.5% complete responses. Median progression-free survival was 8.5 months and overall survival 22 months.
Exploratory analyses also identified distinct metabolic and microbial signatures associated with L-glutamine.
@jgong15
@BhuteShrikant
@1jvaneyk
@DrArsenOsipov
@JLorber_HemeOnc
@sandbillet
@thomasgraeber
@DrHendifar
@BhowmickNeil
@CathyEngMD
@BenWestphalen
@graokane
@NiuSanford
@AndresC27622123
@GillSharlene
@pashtoonkasi
@DrVilmaPBarcia
@Erman_Akkus
@GIMedOnc
@UOzkerim
@MarioBalsaMD
@p_ciracimd
@DraMartinezLago
@DaisukeKotani
@Aiims1742
@ARosen380
@realbowtiedoc
@KoheiShitara
@c_eng1
@sharlenegill
@alicat380
@erman_akkus__
@ninan1230
@shitarakohei
Grainne O'Kane retweeted
This is Grainne O’Kane who is the Pat Smullen Chair in UCD.
Here she is telling us of some brilliant breakthrough news about Pancreatic Cancer.
Grainne is doing the full 95km cycle.
She is a legend.
She does an amazing job 👏👏
💜Historic and incredible moment for patients with pancreatic cancer #PDAC
⭐️Daraxonrasib FDA approved
🙏we need global access & a quick #EMA approval
@pancanireland @P_C_E_ @cancertrials_ie @myESMO
The FDA 🇺🇸 approved daraxonrasib, a first-in-class RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or cannot receive multiagent treatment. Taken daily, the drug targets RAS proteins that drive tumor growth.
✅️ The approval, issued ahead of schedule, provides a new treatment option for a cancer with limited therapies and poor outcomes. #PancreaticCancer
buff.ly/5r4Q5Fb
@CathyEngMD
@BenWestphalen
@graokane
@NiuSanford
@AndresC27622123
@GillSharlene
@pashtoonkasi
@DrVilmaPBarcia
@Erman_Akkus
@GIMedOnc
@UOzkerim
@MarioBalsaMD
@p_ciracimd
@DraMartinezLago
@DaisukeKotani
@Aiims1742
@ARosen380
@realbowtiedoc
@KoheiShitara
@MarioBalsaMD
@realbowtiedoc
@p_ciracimd
@c_eng1
@sharlenegill
@alicat380
@erman_akkus__
@ninan1230
@shitarakohei
Grainne O'Kane retweeted
The FDA 🇺🇸 approved daraxonrasib, a first-in-class RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or cannot receive multiagent treatment. Taken daily, the drug targets RAS proteins that drive tumor growth.
✅️ The approval, issued ahead of schedule, provides a new treatment option for a cancer with limited therapies and poor outcomes. #PancreaticCancer
buff.ly/5r4Q5Fb
@CathyEngMD
@BenWestphalen
@graokane
@NiuSanford
@AndresC27622123
@GillSharlene
@pashtoonkasi
@DrVilmaPBarcia
@Erman_Akkus
@GIMedOnc
@UOzkerim
@MarioBalsaMD
@p_ciracimd
@DraMartinezLago
@DaisukeKotani
@Aiims1742
@ARosen380
@realbowtiedoc
@KoheiShitara
@MarioBalsaMD
@realbowtiedoc
@p_ciracimd
@c_eng1
@sharlenegill
@alicat380
@erman_akkus__
@ninan1230
@shitarakohei
Grainne O'Kane retweeted
Celebrating 20 years of #ILCA in the heart of Europe! 🇧🇪
Last spots are still available for #ILCA26 .
Join +50 global experts for 3 days of practice-changing science, live debates, and premier networking.
Don't miss out - claim your place today!
🔗mcibrussels-pco.swoogo.com/i…
Grainne O'Kane retweeted
Gonna be our favorite slide deck for future talks!
Congratulations! 🎆 A wonderful companion piece to the resistance paper by two friends and outstanding GI oncologists, Teresa Macarulla and Grainne O’Kane (with Paula Lynch). @MacarullaTeresa @graokane
They beautifully put the new biology into perspective and outline where the field is headed next. From understanding resistance to designing smarter, biology-driven combination strategies.
A thoughtful and balanced review! – at Manhattan, NY
The first map of acquired resistance to the tri-complex RAS(ON) inhibitor daraxonrasib in PDAC published today in @NatureMedicine nature.com/articles/s41591-0…
The biology converges on KRAS amplification, MAPK reactivation, PI3K signaling, MYC and cell-state plasticity (partial EMT), providing a strong rationale for mechanism-based combination strategies to achieve deeper and more durable responses.
Outstanding work by Ida Aronchik, Sumit Kar, Kevin Lin, Andy Aguirre, Mallika Singh and the entire multidisciplinary team.
Excited to see where the field goes next. 💜💜
#KRAS #RAS #PancreaticCancer #sPARKlab #GRIT
@RevMedicines @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @OncoAlert @oncodaily @OncBrothers @PanCAN @letswinpc @NatPancFdn @Pankind_Aus @KRASKickers
Grainne O'Kane retweeted
Was skeptical of organ transplant for stage IV ca, but studies like TransMet (CRC liver mets) & now lung transplant suggest meaningful dz control possible.
Many practical q’s re: pt selection, organ allocation, insurance cov, longer f/u…but if it were me, would want the option.
I am happy to share our first comprehensive report of the DREAM study outcome just published in the journal JAMA! 🩺
Historically, lung transplantation has not been offered to patients with advanced lung cancer due to concerns over poor oncological outcomes. Our prospective registry study challenges this paradigm for a highly selected group of patients. 🫁
I am incredibly grateful for the entire DREAM team, including @AnkitBharatMD, who worked tirelessly to care for this challenging group of patients while pushing the frontline of medicine forward. 🙏
Here are the key takeaways from our newly published research:
🔍 The Study Design
Participants: We evaluated 98 adults with medically refractory, “lung-limited”, stage IV non-small cell lung cancer (NSCLC) experiencing respiratory failure.
The Cohorts: 17 patients underwent lung transplantation using a dissemination-minimizing technique, while 81 eligible patients received standard medical management alone due to nonbiologic barriers. We also compared outcomes against 306 adults without cancer who underwent lung transplants.
📈 Promising Survival Outcomes
100% vs 40.8%: The estimated 1-year overall survival was 100% in the lung transplant group compared to just 40.8% for those who received medical management alone, a striking absolute difference of 59.2 percentage points!
📊 Excellent Post-Transplant Success: The 1-year posttransplant survival for stage IV NSCLC patients (100%) was highly favorable, even when compared to transplant recipients without cancer (88.1%).
💡 What This Means
For carefully selected patients with medically refractory, lung-limited, stage IV NSCLC, lung transplantation can offer exceptionally favorable early survival compared to traditional medical management alone. While longer-term follow-up and quality-of-life assessments are still needed, these findings open a crucial new door for advanced lung cancer care. 🚪
🔗 Read the full paper here: jamanetwork.com/journals/jam…
#LungCancer #LungTransplant @LurieCancer @NUFeinbergMed @NM_Lung @IASLC @LUNGevity @TheCancerLetter @OncoAlert @oncodaily @JAMAOnc @ASCO @myESMO @ISHLT @ttsorg @TheJHLT @amjtransplant @UNOSNews @SWOG @SupportingSWOG @WarOnCancer @EGFRResisters @ALKPositiveinc @targetcancer @OncodailyLung @ACSNews
